Full archive
Pharmacogenomics
Week of 4 August 2026
11 articles
Geno'X Veille — genox-veille.fr
Key takeaways this week
- ►NAT2 — the CPIC curation expert panel assigns clinical function to all 59 star alleles (2 increased, 40 decreased, 17 uncertain or unknown) and retires the historical rapid and slow labels; in parallel, a meta-analysis of 67 studies and nearly 14,000 individuals confirms a three-fold risk of anti-tuberculosis hepatotoxicity in slow acetylators (OR 3.14).
- ►MT-RNR1 — UK CERSI-PGx guideline: avoid aminoglycosides at any detectable level of the three mitochondrial variants, carried by about 1 in 330 individuals.
- ►CYP3A4 — in more than 400,000 antihypertensive users, the CYP3A4 22 allele predicts switching away from dihydropyridine calcium channel blockers (OR 1.23) and the NTSR1 G301R variant is associated with less frequent ACEI-induced cough (OR 0.39).
- ►Proxy variants — the same flaw in two actionable genes: two new haplotypes redefine the CYP2C19 2 allele by c.681G>A alone (frequency ~0.03 %), and one patient in 2007 carries the DPYD c.1236G>A proxy without the causal c.1129-5923C>G variant.
11 articles of 11
Sort
NAT2
PubMed★ Top pick
⭐ À la une
Clinical Function Assignment of NAT2 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel
NAT2 acetylator status and drug response
9
New recommendation
Clin Pharmacol Ther 2026· AugRead
CYP3A4
PubMed★ Top pick
Side effects in hypertension treatment: a pharmacogenomic analysis
Antihypertensive drug side effects
9
New interactionAdverse reaction
Eur Heart J 2026· AugRead
MT-RNR1
PubMedMT-RNR1 genotype testing for preventing aminoglycoside-mediated ototoxicity: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx)
Aminoglycoside-induced sensorineural hearing loss
7
New recommendationPreemptive genotyping
Br J Clin Pharmacol 2026· JulRead
DPYD
PubMedDPYD Genotyping of Patients with Fluoropyrimidine Treatment: Results of Protocol Implementation and Outcomes of Patients Carrying Unusual DPYD Variants
Fluoropyrimidine toxicity
6
OncologyCPIC Level ADose recommendation
Genes (Basel) 2026· JulRead
NAT2
PubMedImpact of NAT2 acetylation phenotype on toxicity in tuberculosis therapy: a systematic review and meta-analysis
Anti-tuberculosis drug-induced hepatotoxicity
6
Adverse reaction
Pharmacogenomics 2026· JulRead
CYP2D6
PubMedCYP2D6 Metabolizer Phenotype Is Associated with Early Antidepressant Discontinuation in the UK Biobank
Early antidepressant discontinuation
6
PsychiatryCPIC Level A
Pharmaceuticals (Basel) 2026· JulRead
CYP3A5
PubMedEffects of CYP3A4, CYP3A5, and ABCB1 genetic variants on tacrolimus metabolism during the early period after kidney transplantation
Kidney transplantation and tacrolimus exposure
6
CPIC Level ADose recommendation
Pharmacogenomics J 2026· JulRead
CYP2C9
PubMedThe Effect of Dicloxacillin Administration on Pharmacokinetics of Narrow Therapeutic Window Drugs: Phenytoin and Warfarin
Drug-drug interaction and anticoagulation
6
DiabetesPhenoconversionNew interaction
Clin Pharmacol Ther 2026· AugRead
CYP2C19
PubMedPharmacogenomic landscape in Thailand: Array-based profiling and EMR-linked medication exposure
Pharmacogenomic implementation in a Thai population
6
Preemptive genotypingCPIC Level A
PLoS One 2026· AugRead
ABCB1
PubMedAssociation between venetoclax concentration and febrile neutropenia in acute leukemia: a retrospective analysis
Venetoclax-associated febrile neutropenia in acute leukemia
5
Adverse reaction
Eur J Clin Pharmacol 2026· AugRead
CYP2C19
PubMedCYP2C19 c.681G>A Is not in Complete Linkage Disequilibrium With c.332-23A>G: Implications for Pharmacogenetic Testing
CYP2C19 genotype interpretation
5
CardiologyRecurrent variantCPIC Level A
Clin Transl Sci 2026· JulRead
References and sources
- NAT2 — NAT2 acetylator status and drug response. Clin Pharmacol Ther 2026. PMID 42538601. Score 9/10. https://pubmed.ncbi.nlm.nih.gov/42538601/
- DPYD — Fluoropyrimidine toxicity. Genes (Basel) 2026. PMID 42510779. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42510779/
- MT-RNR1 — Aminoglycoside-induced sensorineural hearing loss. Br J Clin Pharmacol 2026. PMID 42524757. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/42524757/
- NAT2 — Anti-tuberculosis drug-induced hepatotoxicity. Pharmacogenomics 2026. PMID 42531284. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42531284/
- CYP3A4 — Antihypertensive drug side effects. Eur Heart J 2026. PMID 42545033. Score 9/10. https://pubmed.ncbi.nlm.nih.gov/42545033/
- CYP2D6 — Early antidepressant discontinuation. Pharmaceuticals (Basel) 2026. PMID 42515713. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42515713/
- CYP3A5 — Kidney transplantation and tacrolimus exposure. Pharmacogenomics J 2026. PMID 42527396. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42527396/
- ABCB1 — Venetoclax-associated febrile neutropenia in acute leukemia. Eur J Clin Pharmacol 2026. PMID 42541584. Score 5/10. https://pubmed.ncbi.nlm.nih.gov/42541584/
- CYP2C19 — CYP2C19 genotype interpretation. Clin Transl Sci 2026. PMID 42535320. Score 5/10. https://pubmed.ncbi.nlm.nih.gov/42535320/
- CYP2C9 — Drug-drug interaction and anticoagulation. Clin Pharmacol Ther 2026. PMID 42544696. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42544696/
- CYP2C19 — Pharmacogenomic implementation in a Thai population. PLoS One 2026. PMID 42545959. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42545959/
